Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) is anticipated to issue its Q1 2025 quarterly earnings data before the market opens on Thursday, May 1st. Analysts expect Bicycle Therapeutics to post earnings of ($0.86) per share and revenue of $8.67 million for the quarter.
Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last announced its quarterly earnings results on Tuesday, February 25th. The company reported ($0.75) earnings per share for the quarter, beating the consensus estimate of ($0.85) by $0.10. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The business had revenue of $3.70 million for the quarter, compared to analysts' expectations of $5.47 million. During the same quarter last year, the firm earned ($1.16) EPS. The firm's revenue for the quarter was down 30.2% compared to the same quarter last year. On average, analysts expect Bicycle Therapeutics to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.
Bicycle Therapeutics Stock Down 0.8 %
Bicycle Therapeutics stock traded down $0.07 during midday trading on Tuesday, reaching $8.33. The stock had a trading volume of 20,050 shares, compared to its average volume of 395,576. The firm's 50-day moving average price is $8.92 and its 200 day moving average price is $14.81. Bicycle Therapeutics has a 12 month low of $6.10 and a 12 month high of $28.67. The firm has a market capitalization of $576.45 million, a PE ratio of -2.53 and a beta of 1.40.
Wall Street Analyst Weigh In
BCYC has been the subject of a number of research reports. HC Wainwright reaffirmed a "buy" rating and issued a $33.00 price objective on shares of Bicycle Therapeutics in a research note on Wednesday, February 26th. Needham & Company LLC reissued a "buy" rating and set a $30.00 price target on shares of Bicycle Therapeutics in a research report on Wednesday, April 9th. Finally, Stephens restated an "equal weight" rating and issued a $15.00 price objective on shares of Bicycle Therapeutics in a report on Wednesday, January 22nd. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $29.14.
Get Our Latest Stock Report on Bicycle Therapeutics
About Bicycle Therapeutics
(
Get Free Report)
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.
Read More
Before you consider Bicycle Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicycle Therapeutics wasn't on the list.
While Bicycle Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
